Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) dropped 5.5% during trading on Thursday. The stock traded as low as $3.35 and last traded at $3.41. Approximately 435,719 shares traded hands during mid-day trading, an increase of 67% from the average session volume of 261,100 shares. The stock had previously closed at $3.61.
Aadi Bioscience Trading Down 5.5%
The stock’s 50 day moving average price is $4.29 and its 200 day moving average price is $4.12. The company has a market capitalization of $84.22 million, a price-to-earnings ratio of -1.50 and a beta of 0.68.
Aadi Bioscience Company Profile
Aadi Bioscience, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for genetically defined cancers. The company’s primary product is FYARRO, an albumin-bound formulation of sirolimus designed to deliver the mTOR inhibitor to tumors.
FYARRO is approved by the U.S. Food and Drug Administration for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare type of soft-tissue cancer.
Further Reading
- Five stocks we like better than Aadi Bioscience
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}